Form 4: Fractyl Health CFO Increases Stake in Open Market

Fractyl Health CFO Lara Smith Weber purchased 20,000 shares of common stock in an open market transaction.

Summary

• Lara Smith Weber, Chief Financial Officer of Fractyl Health, Inc., acquired 20,000 shares of common stock.
• The purchase was executed on June 8, 2026, at a weighted average price of $0.6854 per share.
• The transaction prices ranged from $0.6844 to $0.6896 per share.
• Following this transaction, the reporting person holds 20,000 shares directly.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a moderately positive signal, as CFO-level insider buying typically indicates confidence in the company's financial trajectory.

Positives

• Insider confidence is demonstrated by the CFO's decision to purchase shares with personal capital.
• The purchase was made on the open market, signaling alignment with shareholder interests.

Negatives

• The purchase volume is relatively small in the context of total outstanding shares.

Risks

• The stock is trading at a low price point, which may reflect broader market concerns regarding the company's valuation or clinical development progress.

Future Outlook

No specific forward-looking guidance was provided in this filing.

Industry Context

StockSavvy.ai notes that insider buying at low price points is often viewed by the market as a signal that management believes the current valuation does not reflect the company's long-term potential, particularly in the biotech sector.

Comparison to Industry Standards

• Insider buying is generally considered a positive signal across the biotechnology industry, suggesting management's belief in the underlying pipeline value.

Stakeholder Impact

• Shareholders may interpret this as a sign of management's commitment to the company's long-term success.

Next Steps

• Monitor future SEC filings for additional insider activity or changes in beneficial ownership.

Key Dates

Recommendation

While insider buying is a positive signal, a single purchase by an executive does not fundamentally change the investment thesis for a biotech company; investors should wait for further clinical or financial catalysts.

Keywords

Fractyl Health, GUTS, Insider Trading, CFO, Stock Purchase, SEC Form 4